Exelixis reported revenue of approximately $628.7 million for the second quarter of 2026, missing Wall Street consensus estimates. While adjusted earnings of $0.91 per share actually exceeded analyst projections, the market focused on the top-line deficit and the company's decision to lower its full-year 2026 revenue outlook. Leadership at Exelixis cited a slower-than-anticipated performance in its neuroendocrine-tumor business as the primary factor behind the reduced forecast.

Levi & Korsinsky, a firm specializing in shareholder class actions, is now examining whether Exelixis provided materially misleading information to investors. The investigation specifically targets the period surrounding the second-quarter report and the revised financial guidance. Investors who incurred losses following these disclosures are being encouraged to submit their trade records for a contingency-based evaluation, regardless of whether they currently hold the stock or have already sold their positions.